Drug Monograph

Drug Name: **Susvimo™ (ranibizumab) vial**
Drug Class: **Immunologic Agents: Vascular Endothelial Growth Factor (VEGF) Monoclonal Antibody**
Prepared For: MO HealthNet
Prepared By: Conduent

☒ **New Criteria** ☐ **Revision of Existing Criteria**

Executive Summary

Purpose:	The purpose of this monograph is to provide a review of new therapy to determine whether the reviewed drug should be made available on an open access basis to prescribers, require a clinical edit or require prior authorization for use.
Dosage Forms:	Susvimo is available in a single-dose vial containing 100 mg/ml of ranibizumab.
Manufacturer:	Manufactured by: Genentech, Inc., South San Francisco, CA 94080.
Indications:	Susvimo is indicated for the treatment of patients with Neovascular (wet) Age-related Macular Degeneration (AMD) who have previously responded to at least two intravitreal injections of a VEGF inhibitor.
Costs:	$8,000 per kit or vial Wholesale Acquisition Cost
Summary of Findings:	MO HealthNet Division recommends Open Access status for this product.

Status Recommendation:	☐ Clinical Edit ☒ Open Access	☐ PA Required ☐ PDL
Type of PA Criteria:	☐ Appropriate Indications ☒ No PA Required	☐ Non-Preferred ☐ Preferred

Prepared by: April Ash, PharmD
Date: February 12, 2022